Surrozen, Inc.
A clinical-stage biotech that turns the body's own repair signals into medicines, Surrozen builds antibody drugs that mimic Wnt proteins — the natural molecules that tell tissue to regenerate. Founded in 2015 by Stanford and other scientists, its lead work targets sight-threatening eye diseases like wet age-related macular degeneration. The name blends "surrogate" and "zen": the engineered antibodies act as stand-ins for the body's repair messengers, long considered impossible to turn into drugs.
Warrant expiring August 1, 2031
Granted 5.91M · Sold 90.0K
Granted 5.91M · Sold 90.0K
Granted 4.03M · Sold 90.0K
Granted 5.91M · Sold 90.0K
Granted 3.50M
Bought 65.6K
Bought 610.8K
Bought 1.39M
Bought 199.1K
Bought 1.00M
Bought 193.5K
Granted 9.6K
Granted 30.0K
Granted 30.0K
Granted 30.0K
Granted 27.2K
Granted 15.6K · Sold 3.5K
Granted 53.4K · Bought 1.5K · Sold 4.8K
Granted 53.1K · Bought 1.5K · Sold 4.5K
Granted 607
Sold 5.38M
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Livingston Kevin HaroldFormer Chief Financial Officer · 13 transactions | — | 8.22Mas of Aug 2021 | 5.91M | — | 90.0K |
| Soffer BennyFORMER DIRECTOR · 13 transactions | — | 5.29Mas of Aug 2021 | 5.91M | — | 90.0K |
| Blutt Mitchell J MDDirector · 8 transactions | — | 4.88Mas of May 2021 | 4.03M | — | 90.0K |
| Consonance Life SciencesFormer 10% Holder · 13 transactions | — | 4.53Mas of Aug 2021 | 5.91M | — | 90.0K |
| Blutt Mitchell J MD +2 co-filers10% owner · 9 transactions | — | 3.81Mas of Aug 2021 | 3.50M | — | — |
| Svennilson Peter +6 co-filers10% owner · 12 transactions | — | 2.26M | — | 65.6K | — |
| Kutzkey TimDirector, 10% owner · 20 transactions | — | 2.26M | — | 610.8K | — |
| Column Group III GP, LP +5 co-filers10% owner · 9 transactions | — | 2.20M | — | 1.39M | — |
| TCG Crossover Fund II, L.P. +3 co-filers10% owner · 20 transactions | — | 1.47M | — | 199.1K | — |
| Blutt Mitchell J MD +3 co-filersDirector, 10% owner · 3 transactions | — | 1.43Mas of Dec 2020 | — | 1.00M | — |
| Column Group III GP, LP +2 co-filers10% owner · 2 transactions | — | 616.5Kas of Apr 2024 | — | 193.5K | — |
| Vanhove GeertruiChief Medical Officer · 1 transaction | — | 32.4Kas of Dec 2022 | 9.6K | — | — |
| Haqq ChristopherFormer Director · 1 transaction | — | 30.0Kas of Aug 2021 | 30.0K | — | — |
| Jarrett JenniferFormer Director · 1 transaction | — | 30.0Kas of Aug 2021 | 30.0K | — | — |
| Santel Donald JFormer Director · 1 transaction | — | 30.0Kas of Aug 2021 | 30.0K | — | — |
| Yeh Wen-ChenChief Scientific Officer · 2 transactions | — | 27.2Kas of Jun 2023 | 27.2K | — | — |
| Li YangExec. Vice President, Research · 12 transactions | — | 20.3K | 15.6K | — | 3.5K |
| Williams Charles OChief Operating Officer · 14 transactions | — | 18.2K | 53.4K | 1.5K | 4.8K |
| Parker Craig CChief Executive Officer, Director · 10 transactions | — | 18.2K | 53.1K | 1.5K | 4.5K |
| Maleki Andrew PedrumChief Financial Officer · 1 transaction | — | 607 | 607 | — | — |
| Blutt Mitchell J MD +5 co-filers10% owner · 4 transactions | — | 0as of Dec 2022 | — | — | 5.38M |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -2.30M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.